To view enhanced content for this article go to http://www.medengine.com/Redeem/75D4F06043F0A7DE.
Androgen deprivation therapy (ADT) is the mainstay palliative treatment for men with locally advanced and metastatic prostate cancer, and aims to reduce testosterone to levels obtained by surgical castration. Use of gonadotropin-releasing hormone (GnRH) agonists predominates among the ADT options. The GnRH agonist, triptorelin is a first-line hormonal therapy that has demonstrated efficacy and safety in clinical trials of patients with locally advanced non-metastatic or metastatic disease. Sustained-release 1-, 3- and 6-month formulations of triptorelin, administered intramuscularly or subcutaneously, have been developed to provide improved flexibility and convenience for the patient. Head-to-head studies of GnRH agonists are lacking in the field of prostate cancer. Despite the inevitable progression to castration-resistant prostate cancer (CRPC) in most patients receiving ADT, monitoring of testosterone levels needs to improve in routine practice and physicians should not overlook the benefits of continued ADT in their patients when introducing one of the various new treatment options for CRPC. For improved survival outcomes, there remains a need to tailor ADT treatment regimens, novel hormonal agents and chemotherapy according to the individual patient with advanced prostate cancer.
National Cancer Institute. SEER Stat Fact Sheet: Prostate Cancer. 2012. http://seer.cancer.gov/statfacts/html/prost.html. Accessed 1 Dec 2016.
Mottet N, Bellmunt J, Briers E, et al. Guidelines on prostate cancer. 2016. Available at: https://uroweb.org/guideline/prostate-cancer/.
Huggins C, Hodges CV. Studies on prostatic cancer 1: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;19:293–7.
Sobin LH, Gospodarowicz MK, Wittlekind C. TNM classification of malignant tumors. 7th ed. Oxford: Wiley-Blackwell; 1999.
Lukka H, Warde P, Pickles T, et al. Controversies in prostate cancer radiotherapy: consensus development. Can J Urol. 2001;8:1314–22. PubMed
Astellas Pharma. Xtandi (enzalutamide). Summary of product characteristics. 2015. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002639/WC500144996.pdf.
Ipsen Ltd. Decapeptyl SR. 3 mg. Summary of product characteristics. 2015. Available at: https://www.medicines.org.uk/emc/medicine/868.
Ipsen Ltd. Decapeptyl SR. 11.25 mg. Summary of product characteristics. 2015. Available at: https://www.medicines.org.uk/emc/medicine/13851.
Ipsen Ltd. Decapeptyl SR. 22.5 mg. Summary of product characteristics. 2015. Available at: https://www.medicines.org.uk/emc/medicine/24154.
Lebret T, Rouanne M, Hublarov O, et al. Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer. Ther. Adv Urol. 2015;7:125–34. CrossRef
Lee CR. Thrombosis and anti-thrombotic therapy. In: Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, editors. Wintrobe’s clinical hematology. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1993. p. 1533.
Bertaglia V, Tucci M, Fiori C, et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. Clin Genitourin Cancer. 2013;11(325–30):e1. PubMed
Kuhn JM, Abourachid H, Brucher P, et al. A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer. Eur Urol. 1997;32:397–403. PubMed
Abbou CC, Lucas C, Leblanc V. Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptorelin in patients with metastatic prostate cancer. Prog Urol. 1997;7:984–95. PubMed
Martinez-Pineiro L, Schalken JA, Cabri P, Maisonobe P, de la Taille A, Triptocare Study Group. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer. BJU Int. 2014;114:608–16. CrossRefPubMed
de la Taille A, Martinez-Pineiro L, Cabri P, Houchard A, Schalken J. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen deprivation therapy. BJU Int. 2016 (epub ahead of print).
Mounedji N, Lundstrom EA, Purcea D, Grosgurin P, Porchet HC. Efficacy of triptorelin in lowering serum testosterone (sT) in patients with advanced prostate cancer. J Clin Oncol. 2011;29(Suppl. 7):A162.
Mason M, Maldonado Pijoan X, Steidle C, et al. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide. Clin Oncol (R Coll Radiol). 2013;25:190–6. CrossRefPubMed
Shore ND, Sieber P, Schimke L, Perzin A, Olsen S. Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer. Urol Nurs. 2013;33(236–44):48.
Cornford P, Jefferson K, Cole O, Gilbody JS, Nayar V, Auddy G. Switching to a 6-monthly triptorelin formulation for prostate cancer (Pca) reduces patient-Nhs interactions and hospital resource use: real world evidence (Rwe) from project deserve (decapeptyl service evaluation). Value Health. 2015;18:A483. CrossRefPubMed
Uttley L, Whyte S, Gomersall T, et al. Degarelix for treating advanced hormone-dependent prostate cancer: a single technology appraisal. Sheffield, UK: ScHARR, University of Sheffield; 2013.
Kunath F, Grobe HR, Rucker G, et al. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database Syst Rev. 2014;6:CD009266. PubMed
James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–77. CrossRefPubMedPubMedCentral
National Center for Biotechnology Information. PubChem Compound Database. https://pubchem.ncbi.nlm.nih.gov/compound/25080282. Accessed 26 May 2016.
National Center for Biotechnology Information. PubChem Compound Database. https://pubchem.ncbi.nlm.nih.gov/compound/25074469. Accessed 26 May 2016.
- An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
Axel S. Merseburger
Marie C. Hupe
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II